Tasigna 150mg ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
34	Neurofibromatosis	1

34. Neurofibromatosis

---

Clinical trials : 137 /  Drugs : 213 - (DrugBank : 76) / Drug target genes : 87 - Drug target pathways : 200

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2012-003005-10-DK (EUCTR)	06/06/2013	08/05/2013	LOW-GRADE GLIOMA	PHASE I-II STUDY OF VINBLASTINE IN COMBINATION WITH NILOTINIB IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH REFRACTORY OR RECURRENT LOW-GRADE GLIOMA - Vinilo	Children, adolescents and young adults with refractory or recurrent low-grade gliomas, and children, adolescents and young adults with neurofibromatosis type 1 and previously untreated low-grade gliomas MedDRA version: 20.0;Level: PT;Classification code 10065443;Term: Malignant glioma;System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0;Classification code 10038111;Term: Recurrent cancer;Classification code 10070308;Term: Refractory cancer;System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps);Therapeutic area: Diseases [C] - Cancer [C04]	Product Name: Nilotinib Product Code: AMN107 Other descriptive name: NILOTINIB HYDROCHLORIDE MONOHYDRATE Trade Name: Tasigna 150mg Product Name: Nilotinib INN or Proposed INN: NILOTINIB Trade Name: Tasigna 200mg Product Name: Nilotinib INN or Proposed INN: NILOTINIB Product Name: Vinblastine Other descriptive name: VINBLASTINE SULPHATE Trade Name: Tasigna 50 mg Product Name: Nilotinib INN or Proposed INN: NILOTINIB	Gustave Roussy	NULL	Not Recruiting			Female: yes Male: yes	160	Phase 2	France;Spain;Denmark;Netherlands;Switzerland